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Abstract
Background: MLL2, an epigenetic regulator in mammalian cells, mediates histone 3 lysine 4 tri-methylation 
(H3K4me3) through the formation of a multiprotein complex. MLL2 shares a high degree of structural similarity with 
MLL, which is frequently disrupted in leukemias via chromosomal translocations. However, this structural similarity is 
not accompanied by functional equivalence. In light of this difference, and previous reports on involvement of 
epigenetic regulators in malignancies, we investigated MLL2 expression in established cell lines from breast and colon 
tissues. We then investigated MLL2 in solid tumors of breast and colon by immunohistochemistry, and evaluated 
potential associations with established clinicopathologic variables.
Results: We examined MLL2 at both transcript and protein levels in established cell lines from breast and colon 
cancers. Examination of these cell lines showed elevated levels of MLL2. Furthermore, we also identified incomplete 
proteolytic cleavage of MLL2 in the highly invasive tumor cell lines. To corroborate these results, we studied tumor 
tissues from patients by immunohistochemistry. Patient samples also revealed increased levels of MLL2 protein in 
invasive carcinomas of the breast and colon. In breast, cytoplasmic MLL2 was significantly increased in tumor tissues 
compared to adjacent benign epithelium (p < 0.05), and in colon, both nuclear and cytoplasmic immunostaining was 
significantly increased in tumor tissues compared to adjacent benign mucosa (p < 0.05).
Conclusion: Our study indicates that elevated levels of MLL2 in the breast and colon cells are associated with 
malignancy in these tissues, in contrast to MLL involvement in haematopoietic cancer. In addition, both abnormal 
cellular localization of MLL2 and incomplete proteolytic processing may be associated with tumor growth/progression 
in breast and colonic tissues. This involvement of MLL2 in malignancy may be another example of the role of 
epigenetic regulators in cancer.
Background
MLL2 (MLL) [Swiss-Prot: Q9UMN6] is a member of the
MLL/trx family of proteins. It contains several evolution-
arily conserved domains [1] including AT hooks at the N-
terminus, cluster of PHD (plant homeodomain) zinc fin-
gers associated with a bromodomain, and a SET (suppres-
sor of variegation, enhancer of zeste, trithorax) domain at
the C-terminus [1]. The full length MLL2 (MLL2FL) is an
uncleaved precursor protein with a predicted molecular
weight of ~290 kD. MLL2FL precursor protein undergoes
post-translational proteolytic maturation, which is criti-
c a l  t o  i t s  n o r m a l  b i o l o g i c a l  a c t i v i t y  [ 2 ] .  T h e  e n z y m e
responsible for MLL2 cleavage is taspase 1, and its con-
sensus cleavage site (D/GVDD) is at a.a. 2063 [2]. Prote-
olytic cleavage generates a large N-terminus fragment
with a predicted molecular weight of 215 kD, and a
smaller C-terminus fragment which separates at ~75 kD
in a denaturing gel. The cleaved fragments subsequently
associate to generate a stable, functional, noncovalent
heterodimeric complex [2].
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The SET domain of MLL2 possesses histone H3 lysine
4 (H3K4) methyltransferase activity, and is an important
component of the multi-protein complex involved in epi-
genetic gene regulation and embryonic development [3-
5]. For example, in vitro, MLL2 complex has been shown
to associate with Pax7, a transcription factor, and activate
myogenic genes through H3 K4 methylation [4]. In vivo,
Mll2 is shown to be required for normal embryonic
development in mice [5-7]. A survey of the literature
shows that several proteins with a primary function in
epigenetic regulation and/or embryonic development are
often aberrantly expressed in cancer. This finding is
related to the observation that embryonic development
and tumorigenesis share several common pathways [8].
Furthermore, proteins with chromatin remodeling
motifs, such as PHD zinc fingers and SET domains, are
often aberrantly expressed in tumors [9-11]. Considering
all these features of MLL2, along with its significant
structural similarity to MLL, we suspected that the MLL2
gene or its product may be altered in cancer, similar to it's
paralog MLL, which is directly linked to haematopoietic
tumorigenesis [12]. A literature survey, however, found
only one published report describing MLL2 amplification
through complex chromosomal rearrangements and
duplications in human cancer cell lines [13]. Querying
ONCOMINE, a publicly available source of gene expres-
sion data sets in cancers [14], we identified a few studies
which listed MLL2 as one of the deregulated genes in
some cancers-including melanoma, bladder and lung car-
cinomas-when compared to the corresponding normal
tissues [14]. Subsequently, tissue microarray based pre-
liminary screening in our laboratory also indicated that
MLL2 may be disrupted in certain cancers. We, therefore,
decided to investigate MLL2 expression in breast and
colon cancer cell lines, and then substantiated our find-
ings in archived formalin fixed paraffin embedded (FFPE)
tumor tissues from patients with confirmed diagnoses of
breast and colon cancers.
In order to study MLL2 in breast cancer cells, we
selected a panel of six breast epithelial cell lines repre-
senting non-tumor breast epithelial derived cell lines
(184A1 and MCF 10A) [15], weakly invasive breast tumor
cell lines (T47D and MCF 7) [15,16] and highly invasive
breast tumor cell lines (MDA-MB-157 and MDA-MB-
231) [16]. For investigating MLL2 in colon cancer cells,
we selected three cell lines derived from well-differenti-
ated colon carcinomas (HT29, DLD-1 and Ls174T) [17-
19] and three from poorly differentiated colon carcino-
mas (Lovo, Colo 205 and SW 480) [18,20,21]. We then
substantiated our observations in cell lines by investigat-
ing MLL2 levels in breast and colon cancer tissues. Here
we report that MLL2 expression is disrupted in invasive
tumor cell lines and invasive carcinomas.
Results
MLL2 in breast cancer cell lines
MLL2 protein levels are elevated and MLL2 is incompletely 
processed in highly invasive breast cancer cell lines
Human mammary cell lines--184A1, MCF10A, T47D,
MCF7, MDA-MB-157 and MDA-MB-231--were pro-
cessed to obtain nuclear and cytoplasmic extracts. Analy-
sis of the extracts revealed the presence of a 75 kD
fragment corresponding to the cleaved C-terminal seg-
ment of MLL2 in the nuclear and/or cytoplasmic frac-
tions (Fig. 1A). The nuclear 75 kD signal was strongest in
MCF10a and weakest in MDA-MB-231 and 184A1, while
the cytoplasmic 75 kD signals were very intense in the
more malignant cell lines (Table 1). Besides the 75 kD sig-
nal, in the cytoplasmic fractions of MCF7, MDA-MB-157
and MDA-MB-231, and the nuclear fractions of MDA-
MB-157 and MDA-MB-231 cell lines, an additional signal
was observed at ~290 kD, corresponding to the MLL2FL
(Table 1). The ~290 kD signal was either absent or faint in
the nuclear and cytoplasmic fractions of 184A1, MCF10A
and T47D (Fig 1A). Overall, MLL2 protein levels
increased with increasing malignant potential of the cell
lines.
MLL2 transcript levels are increased in cell lines derived from 
invasive tumors
Examination of MLL2 RNA levels by semi quantitative
reverse transcription polymerase chain reaction (RT-
PCR) in the mammary epithelial cell lines revealed high-
est levels of MLL2 transcript in MDA-MB-231 and least
in 184A1 (Fig 1B). A gradual increase in the MLL2 RNA
levels was observed in the order of 184A1, MCF10a,
T47D, MCF7, MDA-MB-157 and MDA-MB-231.
Taspase 1 levels and its putative MLL2 cleavage site are not 
altered
Examination of endogenous taspase 1 (enzyme responsi-
ble for proteolytic processing of MLL2) protein levels,
revealed bands of consistent intensities in the cytoplas-
mic fractions of the breast cell lines used in this study (Fig
1A). Additionally, analyses of the MLL2 sequences coding
for the taspase 1 cleavage site showed no alterations in
cell lines carrying MLL2FL (data not shown).
MLL2 in colon cancer cell lines
MLL2 protein is elevated and incompletely processed in 
poorly differentiated colon cancer cell lines
Established cell lines from colon cancer tissues--HT29,
DLD-1, Ls174T, Lovo, Colo205 and SW480--were pro-
cessed to obtain nuclear and cytoplasmic extracts. Analy-
sis of these nuclear-cytoplasmic extracts revealed a 75 kD
signal corresponding to the cleaved, C-terminal peptide
of MLL2 in the nuclear and/or cytoplasmic fractions (Fig
1C, Table 2). The 75 kD band was most intense in the
nuclear fractions of HT-29, DLD-1, Ls174T and Lovo,
and least in Colo205 and SW480. In the cytoplasmic frac-Natarajan et al. Cancer Cell International 2010, 10:13
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tions, the cleaved MLL2 appeared in all cell lines except
HT29 and DLD-1. Additionally, Colo205 and SW480 dis-
played abundant levels of uncleaved MLL2FL (Table 2) in
nuclear fractions compared to the cytoplasmic fractions
(Fig 1C).
MLL2 RNA levels are increased in cell lines derived from poorly 
differentiated colonic tumors
MLL2 RNA levels were found to be higher in the colon
cell lines -- Lovo, Colo205 and SW480-compared to HT-
29, DLD-1 and Ls174T (Fig 1D).
Taspase 1 levels and putative cleavage sites are not altered in 
colon cancer cell lines
Immunoblots of the cell line derived fractions were
probed with anti-taspase 1 antibody, which revealed vari-
able amounts of taspase 1 in the cytoplasmic fractions of
the colonic cell lines examined (Fig 1C). DNA sequence
analyses using primers flanking the coding sites for tas-
pase 1 cleavage site in the MLL2 gene revealed no altera-
tions in the colonic cancer cell lines carrying MLL2FL
(data not shown).
MLL2 expression measured by immunohistochemistry, in 
breast tumor and normal adjacent tissues
Patient demography
The results presented in this study originated from
ninety-six female patients with breast carcinoma, ranging
in age from 26 to 89 years, with a mean age of 59 years at
the time of diagnosis. Lymph node (LN) status was avail-
able for 95 (99%) cases. Tumor size was available for 90
(94%) cases and tumor grades were available for 68 (71%)
Table 1: Relative levels of MLL2 protein in mammary epithelial cell lines
Cell lines Origin, 
Description, ER 
status
Nuclear MLL2 Cytoplasmic MLL2
75 kD 290 kD 75 kD 290 kD
(Cleaved) (Uncleaved) (Cleaved) (Uncleaved)
184A1 Normal breast 
epithelium, 
immortalized, ER -
+-+-
MCF10a Normal breast 
epithelium, 
immortalized, ER-
+++ - ++ -
T47D Early stage breast 
carcinoma, 
tumorigenic, non-
metastatic, ER +
++ - +++ -
MCF7 Early stage breast 
carcinoma, 
tumorigenic, non-
metastatic, ER +
++ - + + +
MDA-MB-157 Advanced breast 
carcinoma, 
Tumorigenic and 
metastatic, ER -
+ + + ++ +++ + + +
MDA-MB-231 Advanced breast 
carcinoma, 
Tumorigenic and 
metastatic, ER -
+ + + ++ +++ + + +
Distribution of cleaved and uncleaved MLL2 protein in nuclear and cytoplasmic fractions of normal and tumor derived mammary epithelial 
cell lines
Staining intensity - Negative; + Faint; ++ Weak; +++ Moderate, ++++ IntenseNatarajan et al. Cancer Cell International 2010, 10:13
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cases. Estrogen receptor (ER) and progesterone receptor
(PR) status was known for 88 (92%) and 77 (80%) cases,
respectively. HER-2/neu status was available for 87 (91%)
cases. Overall survival status was known for all, and
recurrence data was available for 95 (99%) cases.
Tumor and benign tissues were present in all (100%)
cases with invasive carcinoma (IC) of the breast. Sixty-
three (66%) were ductal and 33 (34%) were lobular carci-
nomas. LN status was positive in 50/95 (55%), and nega-
tive in 41/95 (45%) cases. Tumor size was ≤ 2 cm for 36/
90 (40%), and >2 cm for 54/90 (60%) cases. Of the sixty-
eight graded tumors, 18 (26%) were well differentiated, 33
(49%) moderately differentiated, and 17 (25%) poorly dif-
ferentiated. There were 81/96 (84%) early stage (1 and 2),
and 15/96 (16%) advanced stage (3 and 4) tumors. ER was
positive in 64/88 (73%) cases while PR in 43/77 (56%)
cases, and 21/87 (24%) cases were HER2/neu positive.
Thirty-seven (38%) cases had post-surgical disease recur-
rence, and 59/96 (62%) had expired.
Immunohistochemically detected MLL2 expression was 
significantly elevated in tumor tissues compared to adjacent 
benign tissue
Cytoplasmic MLL2 immunostaining was increased (Fig.
2A, Table 3) in the malignant tissues in 86/96 (90%) cases
(p < 0.05) compared to benign epithelium from the same
patients (Fig 2B). Cytoplasmic expression correlated with
early tumor stage (p = 0.02), and menopausal status (p =
0.03) (Table 4). Nuclear immunoreactivity was observed
in 43/96 (45%) cases (Fig. 2C) and did not correlate with
Figure 1 Immunoblot images of nuclear cytoplasmic fractions, and gel images of reverse transcription-PCR (RT-PCR) from human mamma-
ry and colonic epithelial cell-lines. (A & C) Cropped immunoblots of nuclear and cytoplasmic extracts from breast (A) and colon (C) cell lines probed 
for MLL2, taspase 1, topoisomerase IIβ (control nuclear protein) and alpha-tubulin (control cytoplasmic proteins). From top, full-length MLL2 (290 kD), 
cleaved C-terminus fragment of MLL2 (75 kD), topoisomerase IIβ and alpha-Tubulin are cropped images from the same blot. (B & D) Total RNA was 
isolated from mammary (B) and colonic (D) epithelial cell lines and subjected to RT-PCR using MLL2 and GAPDH sequence specific primers spanning 
exon-exon junctions. Cropped images of gels showing amplified products loaded on 2% agarose gels. Top- MLL2, bottom- GAPDH. A. Nuclear and 
cytoplasmic fractions from mammary epithelial cell lines from a single blot. B. MLL2 transcript from mammary epithelial cell lines from a single gel. C. 
Nuclear and cytoplasmic fractions from colonic epithelial cell lines from a single blot. D. MLL2 transcript from colonic epithelial cell lines from a single 
gel.Natarajan et al. Cancer Cell International 2010, 10:13
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any of the clinicopathologic variables. Distribution pat-
tern for nuclear immunoreactivity is detailed in Table 3.
MLL2 expression by immunohistochemistry, in tumor and 
adjacent normal tissues of the colon
Patient demography
Sixty-six patients, including 34 (52%) males and 32 (48%)
females, who had invasive carcinoma of the colon were
included in this study. The patients ranged in age from 38
to 92 years, with a mean age of 70 years at diagnosis.
Tumor and benign tissue were present in all 66 cases with
IC of the colon. LN status was positive in 32/66 (49%)
cases, and negative in 34/66 (51%) cases. There were 4/66
(6%) well differentiated, 54/66 (82%) moderately differen-
tiated, and 8/66 (12%) poorly differentiated tumors.
There were 18/66 (27%) early stage (1 and 2), and 48/66
(73%) advanced stage (3 and 4) tumors. Survival status
was available for all cases and 50/66 (76%) patients had
expired.
Immunohistochemically detected MLL2 expression is 
significantly elevated in tumor tissues compared to adjacent 
benign mucosa
Cytoplasmic MLL2 immunostaining was significantly
increased in 63/66 (95%) tumors (p < 0.05) when com-
pared to adjacent benign mucosa (Fig 3A, Table 5). No
correlation was observed between cytoplasmic MLL2
expression and any of the clinicopathologic variables.
Nuclear staining was increased (Fig 3B) in 77% cases (p <
0.05) (Table 5) compared to benign mucosa from the
same cases (Fig 3C). Increased nuclear MLL2 expression
correlated with early stage tumors (p = 0.03) (Table 6) and
absence of LN involvement (p = 0.005) (Table 6).
Table 2: Relative levels of MLL2 protein in colonic cell lines
Cell lines Nuclear MLL2 Cytoplasmic MLL2
75 kD 290 kD 75 kD 290 kD
(Cleaved) (Uncleaved) (Cleaved) (Uncleaved)
HT29 +---
DLD-1 ++ - - -
Ls174T ++ - + -
Lovo +- + + -
Colo205 -+  +  + ++ +  +
SW480 -+  +  + ++ +  +
Distribution of cleaved and uncleaved MLL2 protein in nuclear and cytoplasmic fractions of colon carcinoma cell lines
Staining intensity - Negative; + Weak; +++ Moderate, ++++ Intense
Table 3: Immunohistochemically detected MLL2 expression in human breast tissue (n = 96)
Nuclear MLL2 staining Cytoplasmic MLL2 staining
Positive staining 43/96 (45%) 96/96 (100%)
Tumor vs. Benign
T < B 17/43 (39%) 1/96 (1%)
T = B 8/43 (19%) 9/96 (9%)
T > B 18/43 (42%) 86/96 (90%)*
Distribution of breast cancer cases based on nuclear and cytoplasmic MLL2 immunostaining in tumor versus benign tissues; *p < 0.05Natarajan et al. Cancer Cell International 2010, 10:13
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Discussion
In the present study we observed that: (a) MLL2, primar-
ily regarded as a nuclear protein with nuclear localization
signals, displayed significant cytoplasmic localization in
both normal and malignant cells, (b) mammary and
colonic cell lines derived from highly invasive tumors
exhibited altered sub-cellular distribution and proteolytic
processing of MLL2 compared to non-tumor/less-inva-
sive-tumor cell lines, and (c) MLL2 is overexpressed in
breast and colon tumors tissues compared to the corre-
sponding normal adjacent tissues.
MLL2 is primarily regarded as a nuclear protein. How-
ever, we observed both nuclear and cytoplasmic MLL2 in
cell lines and tissue sections from breast and colon. In the
breast epithelial cell lines, MLL2 specific bands repre-
senting the cleaved (75 kD) protein were observed in the
cytoplasmic fractions of not only the tumor cell lines but
also the non-tumor cell lines, 184A1 and MCF10a (Fig
1A); while bands representing the full-length, unpro-
cessed MLL2 (290 kD) were present in the highly invasive
tumor cell lines alone, and which may be related to onco-
genic activity. The nuclear-cytoplasmic localization pat-
tern of MLL2 was also evident in the benign sections of
both breast and colonic tissues, but it was not possible to
delineate the cleaved from the uncleaved MLL2 as the
antibody used in this study cannot differentiate one from
the other in situ (details of antibody specificity are
described in Methods section). Considering this cyto-
plasmic presence of MLL2 in the non-tumor cell lines
and non-tumor tissue sections, it is possible that MLL2
may have a yet unidentified function in the cytoplasm,
besides its role in epigenetic regulation in the nucleus
[22,23]. However, a notably increased cytoplasmic pres-
ence in the cancer cell lines and cancer tissues, together
with the presence of MLL2FL could be a tumor-related
anomaly resulting from overexpression or increased pro-
tein/RNA stability.
Our study of the breast and colonic cell lines revealed
two notable trends related to the proteolytic processing
of MLL2. First, we observed a gradient in the intensities
Table 4: MLL2 expression and clinicopathological variables in breast cancer (n = 96)
Number of cases positive for 
cytoplasmic MLL2
Number of positive cases where T > B 
(%)
N9 6 86 (90)
Tumor stage
Early (1 & 2) 81 75 (93)*
Advanced (3 & 4) 15 11 (73)
Menopausal status
Pre 20 16 (80)
Post 76 70 (92)**
Clinicopathological variables associated with elevated levels of cytoplasmic MLL2 immunoreactivity in patients with invasive breast cancer; 
*p = 0.02; **p = 0.03
Figure 2 Representative immunohistochemistry staining for 
MLL2 in human FFPE breast tissue sections A. Intense cytoplasmic 
MLL2 immunostaining in epithelial cells (arrows) of tissue section from 
invasive breast carcinoma, ×400. B. Breast tissue showing strong cyto-
plasmic immunoreactivity of MLL2 in invasive ductal carcinoma (solid 
arrow head) cells compared to the adjacent, benign (arrows) mamma-
ry ducts, ×200. C. Strongly positive nuclear (arrow) MLL2 immunostain-
ing in epithelial cells of invasive breast carcinoma tissue section, ×400. 
D. Negative control, ×400.Natarajan et al. Cancer Cell International 2010, 10:13
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of the 75 kD signal in the nuclear fractions of both breast
and colonic cell lines (Fig. 1A &1C). In the breast epithe-
lial cell lines, the intensities of the 75 kD nuclear MLL2,
indicative of normal proteolytic processing, showed a
decreasing trend with increasing malignancy from
MCF10A to MDA-MB-231 except for MCF7. Of these
cell lines, 184A1 and MCF10A are non-tumorigenic,
MCF7 [16] and T47D are tumorigenic [15] but weakly
invasive [24], while MDA-MB-157 and MDA-MB-231
[16] are highly invasive [15,24,25]. The non-tumor cell
line, 184A1, did not fit this trend and this discrepancy
could be attributed to an overall lower level of MLL2 in
184A1, and/or the difference in proliferation rate--184A1
cells are reported to have a relatively lower proliferation
rate compared to MCF10A [25]. In the colonic epithelial
cell lines a similar intensity gradient was noted for the 75
kD nuclear MLL2 fragment. Of these cell lines, HT29
[17], DLD-1 [18] and Ls174T [19] are derived from well-
differentiated tumors while, Lovo [18], Colo205 [20] and
SW480 [21] are derived from poorly differentiated
tumors; and the 75 kD nuclear MLL2 was least in the
Colo205 and SW480 cell lines.
The second notable trend was the presence of an addi-
tional band of 290 kD size (corresponding to the
uncleaved precursor MLL2FL) in the more invasive/
poorly differentiated cell lines. More importantly, the
MLL2FL (290 kD) signal intensity increased in the nuclear
and cytoplasmic fractions as the 75 kD nuclear signal
decreased (Fig. 1A &1C). This uncleaved MLL2FL
observed in the cytoplasmic and nuclear fractions of the
advanced tumor cell lines could be a consequence of
insufficient endogenous taspase 1 required for processing
the excess MLL2. Since proteolytic cleavage could also be
impaired as a consequence of non-cleavable mutations in
Table 5: Immunohistochemically detected MLL2 expression in human colonic tissues
Nuclear MLL2 staining Cytoplasmic MLL2 staining
Positive cases 35/66 (53%) 66/66 (100%)
Tumor vs. Benign
T < B 7/35 (20%) 3/66 (5%)
T = B 1/35 (3%) 0/66 (0%)
T > B 27/35 (77%)* 63/66 (95%)*
Distribution of colon cancer cases based on nuclear and cytoplasmic MLL2 immunostaining in tumor versus benign tissue; * p < 0.05
Table 6: MLL2 expression and clinicopathological variables in breast cancer (n = 96)
Number of cases positive for nuclear 
MLL2
Number of positive cases where T > B 
(%)
35 27 (77)
Lymph node
Negative 20 19 (95)***
Positive 15 8 (53)
Tumor stage
Early 12 11 (92)**
Advanced 23 16 (70)
Clinicopathological variables associated with elevated levels of nuclear MLL2 immunoreactivity in patients with invasive colon carcinoma; 
**p = 0.03; ***p = 0.005Natarajan et al. Cancer Cell International 2010, 10:13
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MLL2FL or the absence/decrease in the endogenous tas-
pase 1 that cleaves MLL2 [2], we looked for mutations in
the  MLL2 sequence coding for taspase 1 cleavage site,
and also examined taspase 1 protein levels in the cell
lines. Sequence analysis of the coding region for taspase 1
cleavage sites in cell lines carrying MLL2FL did not reveal
any alterations in the cleavage site encoding sequences. In
addition, we found that the taspase 1 protein levels did
not vary in parallel with the presence or absence of
MLL2FL. Taspase 1 protein levels were consistent across
the six breast tissue cell lines, irrespective of the presence
of MLL2FL. Although we did not observe consistent levels
of taspase 1 across the colonic cell lines, we did observe
that the presence or absence of MLL2FL and its levels,
failed to correlate with taspase 1 level. That is, higher lev-
els of taspase 1 did not correspondingly correlate with
decreased levels of MLL2FL or its total absence. These
results suggest that the presence of MLL2FL in the inva-
sive cell lines is not a consequence of diminished levels of
taspase 1 or a mutated cleavage site in the MLL2. Further
investigation is required, to determine the cause and con-
sequences of MLL2FL in the nucleus, which might be
related to the shift in the nuclear-cytoplasmic localization
of MLL2 in the invasive cell lines. Whatever may be the
cause, our results suggest that the presence of precursor
MLL2FL is associated with a higher degree of malignancy.
According to an earlier report [2], proteolytic process-
ing of MLL2FL is crucial to its stability, sub-nuclear local-
ization, and methyltransferase activity. Impaired
proteolytic maturation could result in significant changes
in the normal epigenetic regulatory activities of MLL2. It
has been shown in vitro that MLL2 forms a multiprotein
complex with Wdr5-Ash2L [26] and associates with pro-
teins like Pax7 and NF-E2 to direct histone lysine methy-
lation at specific gene loci [3,4]. MLL2 specific histone
methylation complex is also known to associate with the
tumor suppressor protein, menin, and mediate histone
methylation at Hoxc8 locus [27]. Given the critical role
for MLL2 in histone methylation activities, we believe
that proteolytically immature and/or inappropriately
expressed MLL2 may fail to effectively associate with the
other members of the histone-methyltransferase com-
plex, which in turn can adversely affect its role in epige-
netic gene regulation.
In our analysis of the breast and colonic cell lines by
reverse transcription (RT)-PCR, we also observed that
MLL2 RNA levels were highest in the invasive tumor cell
lines and least in the non-tumor/less-invasive-tumor cell
lines (Fig. 1B &1D). This trend in the MLL2 RNA levels
was consistent with our observation of the overall
increase in protein levels in the invasive tumor cell lines
and in the tumor tissues. Since a real-time measurement
was not performed on these cell lines it is not known if
the increased levels of RNA resulted from an increased
rate of transcription. The observed gradient in RNA lev-
els in the breast and colon cell lines could also be due to
differences in RNA stability. Though the RT-PCR results
are not strictly quantitative, the results do indicate that
MLL2 RNA levels are more abundant in the highly inva-
sive/less differentiated cell lines.
Finally, our study on tissue sections from breast and
colon cancer patients revealed that immunohistochemi-
cally detected MLL2 is significantly increased in tumor
tissues. In breast tumors from patient samples, cytoplas-
mic MLL2 was significantly overexpressed as compared
to normal adjacent tissues, and in colon tumors both
cytoplasmic and nuclear MLL2 were significantly overex-
pressed when compared to adjacent benign mucosa.
Since immunohistochemical signals can often arise from
non-specific antibody reactions, we evaluated the speci-
ficity of antibody reactivity using a blocking peptide, a
part of which represented the epitope recognized by anti-
MLL2 antibody (detailed in Methods section). The pep-
tide blocks the ability of the antibody to bind to its anti-
gen. These experiments confirmed a high specificity of
the antibody to the MLL2 antigen (Fig. 3D).
Analysis of MLL2 expression data with clinicopatholog-
ical variables revealed a small correlation between MLL2
overexpression and early tumor stages (breast and colon)
and absence of lymph node involvement (colon). How-
Figure 3 Representative immunohistochemistry staining for 
MLL2 in human FFPE colonic tissue sections. A. Note differential cy-
toplasmic MLL2 immunostaining in tissue section from invasive carci-
noma of the colon (solid arrow) and adjacent normal mucosa (hollow 
arrow), ×400. B. Nuclear immunoreactivity of MLL2 (arrow) in invasive 
colon carcinoma, ×400 C. Weakly positive MLL2 immunostaining in ad-
jacent benign colonic epithelial cells (arrows), ×200 from same patient 
whose tumor sample is shown in (B) D. Anti-MLL2 antibody was incu-
bated with blocking peptide and added to the slide with FFPE colon 
tissue, followed by washing and staining with secondary antibody and 
visualization by using diaminobenzidine (DAB) as a precipitating en-
zyme product.Natarajan et al. Cancer Cell International 2010, 10:13
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ever, the number of cases in each category was too small
and the association too tentative to draw a substantive
conclusion at this juncture. Despite a lack of correlation
with established clinicopathological variables, the ele-
vated levels of MLL2 protein in both breast and colon
cancer was significant. These results are in line with our
observation of increased MLL2 protein and RNA levels in
the cell lines. However, due to the lack of an appropriate
antibody to distinguish the cleaved MLL2 from uncleaved
MLL2FL by immunohistochemistry, we cannot comment
on the composition of the overexpressed protein as to
whether it constituted more of the 75 kD fragment or the
290 kD MLL2FL.  T h e  e l e v a t e d  l e v e l s  o f  M L L 2  i n  t h e
tumor tissues could be the result of overexpression,
genomic amplification, increased RNA and/or protein
stability, or, at least in part, due to alterations in protein
processing. For example, genomic amplification of MLL2
(through complex chromosomal rearrangements or chro-
mosomal duplications) resulting in four MLL2 copies has
been previously reported in one of the breast cancer cell
line, MDA-MB-157, used in this study [13].
Whichever may be the cause, deregulated expression of
MLL2 and/or defective proteolytic processing may
adversely impact MLL2 mediated histone methylation
activities, and in turn, disrupt downstream target genes
potentially involved in cell cycle or cell proliferation
activities. Consequently, aberrantly expressed MLL2
driven epigenetic regulation may contribute to tumor
growth and/or progression. If such is the case, deregula-
tion of MLL2 may be a more generic feature in tumori-
genesis rather than an event specific to a particular tumor
type, as is indicated by our findings in both breast and
colon tumors.
Conclusions
In all, our study shows for the first time that overexpres-
sion of MLL2, an altered subcellular distribution, and
aberrant proteolytic processing may be linked to tumori-
genesis in mammary and colonic tissues. This linkage
may be attributed, at least in part, to the role of MLL2 in
histone methyltransferase activities [22,23]. Given the
well-known role for MLL in leukemias, and the increas-
ing focus on abnormal epigenetic regulation in cancer,
the results of this study present a strong argument for
further investigation of MLL2 and its possible involve-
ment in solid tumors.
Methods
Cell lines, nuclear-cytoplasmic fractionation, 
immunoblotting
Cell lines
All parental cell lines were initially purchased from
American Type Culture Collection (ATCC) and main-
tained at the University's Tissue Culture Core facility.
Human breast epithelial cell lines used in this study
included 184A1, MCF10A, T47D, MCF7, MDA-MB-157
and MDA-MB-231. MCF10A and 184A1, are immortal-
ized human mammary epithelial cell lines derived from
non-tumor breast tissue [15,16]. T47D and MCF7 are
ER+, tumorigenic, non-metastatic, anti-estrogen sensi-
tive cell lines. MDA-MB-157 and MDA-MB-231 are ER-,
tumorigenic, metastatic and anti-estrogen resistant cell
line.
The colonic epithelial cell lines used in this study
included HT29, DLD-1, Ls174T, Lovo, Colo205 and
SW480, and were initially obtained from ATCC and
maintained at the Tissue Culture Core facility of the Uni-
versity. HT29 [17], DLD1 [18] and Ls174T [19] were
established from well differentiated carcinomas while
Lovo [18], Colo205 [20] and SW480 [21] were derived
from poorly differentiated colon carcinomas.
Cell lines were maintained at 37°C, in a humidified
chamber with 5% CO2, in T-175 cm2 tissue culture flasks.
MCF10A was grown in a 1:1 mixture of Ham's-F12
medium and DMEM (Gibco, USA), with 2.5 mM L-glu-
tamine, and supplemented with 20 ng/ml epidermal
growth factor, 0.01 mg/ml insulin, 500 ng/ml hydrocorti-
sone, and 5% horse serum. Cell line 184A1, was grown in
MEGM® (Clonetics®) complete media (10 ng/ml hEGF, 5
ug/ml insulin, 0/5 ug/ml hydrocortisone and bovine pitu-
itary extract). All other breast cell lines were cultured in
DMEM complete media containing 4.5 g/L glucose, 2
mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-
essential amino-acids, and supplemented with 5% fetal
bovine serum (FBS). The colonic epithelial cell lines HT-
29, Ls174T and SW480 were grown in DMEM complete
media. DLD-1 and Colo205 were cultured in RPMI 1640
media supplemented with 10% FBS, 1% Sodium pyruvate
and 1% non-essential amino acids. Lovo was cultured in
Ham's F12K media supplemented with 10% FBS.
Nuclear-Cytoplasmic fractionation
Equal volumes of the cell pellet from each cell line were
used for fractionation following an established protocol
[28]. Known volumes of cell pellets were resuspended in a
hypotonic buffer (HB) (10 mM Tris pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 20% TritonX-100 and protease inhib-
itors (Roche, Germany)), and incubated on ice for 30
minutes with vortexing for 30 s at intervals of 10 minutes.
The suspension was then centrifuged at 1000 g, pellets
were saved, and the supernatant was centrifuged at 7000
r.p.m. in a fresh tube to remove debris. T o the superna-
tant, 5 M NaCl was added to achieve a final concentration
of 200 mM cytoplasmic extract. The saved pellet was
resuspended in high salt concentration buffer C (10 mM
Tris pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 400 mM NaCl,
0.4% TritonX-100 and protease inhibitors) and vortexed
for 30 minutes at 4°C, followed by centrifugation at
20,000 g. The supernatant was transferred to a fresh tubeNatarajan et al. Cancer Cell International 2010, 10:13
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and an equal volume of HB was added to achieve a final
concentration of 200 mM NaCl. This constituted the
nuclear extract.
Immunoblotting and antibodies
Extracts were separated on a 3-8% Tris-acetate denatur-
ing gel (NuPAGE, Invitrogen, USA), and blotted onto a
PVDF membrane. The blots were probed with anti-MLL2
(see Immunohistochemistry section for details) antibody
(1:500) in 5% non-fat dry milk dissolved in tris-buffered
saline with 0.1% Tween-20, followed by goat anti-rabbit
peroxidase conjugated secondary antibody (Santa Cruz
Biotechnology, USA). The blots were subsequently
probed with anti-taspase 1 (Santa Cruz Biotechnology,
USA) (1:200) followed by secondary antibody. As evi-
dence of purity of the nuclear and cytoplasmic fractions,
blots were probed with mouse monoclonal anti-Topoi-
somerase IIβ (1:1000) (BD Biosciences, USA) and anti-
alpha-tubulin (1:5000) (Sigma, USA), respectively. The
signals were detected by incubating the membrane with
ECL chemiluminescent substrate (Immobilon substrate,
Millipore, USA) for 5 minutes and then exposing an X-ray
film (Pierce, USA) for 30 s.
DNA isolation and sequencing
DNA from cell lines were isolated and purified by spin
column (Epicenter® Biotechnologies, WI, USA). PCR was
performed with primers designed to amplify genomic
DNA sequences coding for the putative cleavage site for
taspase 1. The primer sequences were- forward 5'-cag-
gactgagtgctgctgac-3' and reverse 5'-agtatgattttggatgtggcg-
ggt-3'. Amplified PCR products were purified by spin
columns and sequenced at the University's core facility.
RNA isolation and semi-quantitative reverse transcription-
PCR
Total RNA was extracted from cell lines using QIAzol
lysis reagent (Qiagen, USA). Primers were designed span-
ning adjacent exon-exon junctions. Primer sequences
were- forward 5'-tctcacggtgccaagatgg -3' and reverse 5'-
tcggggcgctcgacctcgct -3'. GAPDH (control) primer
sequences were- forward 5'-tgcaccaccaactgcttagc-3'  and
reverse  5'-ggcatggactgtggtcatgag-3'. To determine tran-
script levels of MLL2, one-step reverse transcriptase-
PCR (RT-PCR) was performed using equal amounts of
total RNA from each cell line. Amplified products were
separated on a 2% agarose gel containing ethidium bro-
mide. Gels were imaged using FluorChem™ IS-8900
imaging system, CA, USA (Alpha Innotech).
Patients and Clinicopathology
Mammary Carcinoma
Formalin fixed paraffin embedded (FFPE) tissue sections
from 96 patients who underwent either mastectomy or
local excision for primary invasive mammary carcinoma,
between 1983 and 1997, at the Albany Medical Center
Hospital were randomly selected for the current study.
This study was approved by the Albany Medical Center
Institutional Review Board (IRB). The pathology and
clinical records, tissue blocks, and hematoxylin and eosin
stained slides were retrieved for each case. Slides were
reviewed and samples were identified based upon the
presence of adequate tumor tissue, the representative
nature of the overall grade, and the presence of adjacent
normal (non-tumor) epithelium. Tumor type, age at diag-
nosis, lymph node (LN) status, tumor size, tumor grade,
pathologic stage, estrogen and progesterone steroid hor-
mone receptor status, HER-2/neu status, recurrence, and
overall survival were obtained by review of the medical
records. Menopausal status was considered by defining
premenopausal age as ≤ 55 years, and postmenopausal
age as >55 years. Tumors were graded using the modified
Bloom and Richardson method [29]. This method is also
the accepted standard for grading lobular carcinomas
[29]. All cases were staged according to American Joint
Committee on Cancer [30] criteria, using the TNM clas-
sification scheme, at the time of diagnosis. Estrogen/pro-
gesterone receptor (ER/PR) status was measured by
competitive binding assays and immunohistochemistry
(IHC). HER-2/neu protein status was detected by immu-
nohistochemistry (IHC), or HER-2/neu gene amplifica-
tion status measured by fluorescence in situ hybridization
(FISH), or both.
Colorectal Carcinoma
FFPE tissue sections from 66 patients who underwent
surgery for primary invasive colorectal carcinoma,
between 1990 and 2000, at the Albany Medical Center
Hospital, were randomly selected for the current study.
This study was approved by the Albany Medical Center
IRB. The pathology and clinical records, tissue blocks,
and hematoxylin and eosin stained slides were retrieved
for each case. Slides were reviewed and samples were
identified based upon the presence of adequate tumor tis-
sue, the representative nature of the overall grade, and the
presence of adjacent benign epithelium. LN sta tus was
recorded for all cases. All tumors were graded and staged
according to the Duke's system [31].
Immunohistochemistry
MLL2 Immunostaining
The anti-MLL2 polyclonal antibody [27] was purchased
from Bethyl Labs, Inc., MD, USA (Cat # A300-113A).
This antibody is specific to an epitopic region upstream
of the SET domain at the C-terminus, between residues
2375-2425. The antibody targets uncleaved MLL2FL as
well as cleaved fragments bearing the epitope. The C-ter-
minus fragment resulting from natural proteolytic cleav-
age and processing of MLL2FL is represented by a 75 kD
band in a denaturing gel immunoblot. The uncleavedNatarajan et al. Cancer Cell International 2010, 10:13
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MLL2FL has a predicted molecular weight of 290 kD. The
specificity of the antibody to its target protein, MLL2,
was confirmed by using MLL2 specific blocking peptide
(Cat # BP300-113, Bethyl labs, Inc., MD, USA) in IHC
staining. A part of this blocking peptide represents a por-
tion of the epitope recognized by the anti-MLL2 anti-
body. Anti-MLL2 antibody (1:30 dilution) was mixed
with thirty-fold volumes of the blocking peptide at RT for
0.5 h. This mixture was then added on to a slide with
FFPE colon tissue section and incubated for 3 h. The slide
was then washed and stained with biotin conjugated sec-
ondary antibody, followed by the addition of streptavidin
horseradish peroxidase (HRP) conjugate, and visualized
by using diaminobenzidine (DAB) as a precipitating
enzyme product (Fig. 3D). Other commercially available
antibodies against MLL2 were tested, but not found to be
suitable for this study.
Immunohistochemical staining for MLL2 in breast and
colon tissue sections was performed on the Ventana ES
automated IHC instrument (Ventana Medical Systems,
Inc., Tucson, AZ) with an indirect biotin/avidin system
(Ventana iVIEW detection). Four micron FFPE sections
w e r e  c u t  f r o m  r e p r e s e n t a t i v e  b l o c k s  o f  e a c h  c a s e  a n d
transferred to glass slides. The tissue sections were de-
waxed, rehydrated, and soaked briefly in wash buffer.
Unmasking of the MLL2 antigenic determinant sites was
not necessary. Immunostaining using anti-MLL2 was car-
ried out at a dilution of 1:30, for 3 h, at 37°C. The specific
antibody was localized using a biotin-conjugated second-
ary antibody (1 h), followed by the addition of a streptavi-
din horseradish peroxidase (HRP) conjugate.
Immunoreactivity was visualized by utilizing DAB as a
precipitating enzyme product. Finally, slides were coun-
terstained with hematoxylin. To confirm specificity of
primary antibody, negative control slides were run with
every batch, using Ventana rabbit polyclonal negative
control reagent. Images were acquired using Olympus
BX51 (Tokyo, Japan) light microscope with Qimaging
digital Camera (Tokyo, Japan) and Qcapture Pro51 soft-
ware.
Immunostaining Interpretation
Cytoplasmic and nuclear MLL2 immunoreactivity was
interpreted by a senior pathologist (B.V.S.K), without
prior knowledge of the clinicopathology for each case of
breast or colon carcinoma. Intensity and distribution
were considered by semi quantitative assessment of the
staining pattern. The staining intensity was scored as
negative, weak (W), moderate (M), or intense (I). The
staining distribution was scored as focal (F) (≤ 10%),
regional (R) (11 - 50%), or diffuse (D) (>50%). For analy-
sis, intensity and distribution were given equal weight as
a multiplicative index, obtained by multiplying intensity
by distribution to obtain a total score. Each case was then
assigned to one of three categories as follows: cases in
which the total score for tumor was less than (T < B;
decreased), equal to (T = B), or greater than (T > B;
increased) the adjacent benign tissue in the same case.
Statistical analysis
Statistical comparisons were carried out using the STATA
software (Stata Corporation, College Station, TX). Chi-
square test was used to determine significance of the
associations between protein expression and prognostic
variables. Multivariate analysis, including clinicopatho-
logic parameters and expression of each targeted protein,
was performed using the Cox proportional hazards
model. The level of significance was set at p < 0.05.
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